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3Department of Surgical and Gastroenterological Sciences, University of Padova, ItalySummary IntroductionSeveral cholangiopathies result from a perturbation of develop-
mental processes. Most of these cholangiopathies are character-
ised by the persistence of biliary structures with foetal
conﬁguration. Developmental processes are also relevant in
acquired liver diseases, as liver repair mechanisms exploit a
range of autocrine and paracrine signals transiently expressed
in embryonic life. We brieﬂy review the ontogenesis of the intra-
and extrahepatic biliary tree, highlighting the morphogens,
growth factors, and transcription factors that regulate biliary
development, and the relationships between developing bile
ducts and other branching biliary structures. Then, we discuss
the ontogenetic mechanisms involved in liver repair, and how
these mechanisms are recapitulated in ductular reaction, a com-
mon reparative response to many forms of biliary and hepatocel-
lular damage. Finally, we discuss the pathogenic aspects of the
most important primary cholangiopathies related to altered bili-
ary development, i.e. polycystic and ﬁbropolycystic liver diseases,
Alagille syndrome.
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induced neutrophil chemoattractant; ET-1, endothelin-1.Development of the biliary system is a unique process that has
been thoroughly reviewed in several recent papers [1,2]. Here,
we will focus on those concepts of biliary development that
are ‘‘essential’’ to understand congenital and acquired
cholangiopathies.
Cholangiopathies are an heterogeneous group of liver dis-
eases, caused by congenital, immune-mediated, toxic, infectious
or idiopathic insults to the biliary tree [3,4]. In addition to being
responsible for signiﬁcant morbidity and mortality, cholangiopa-
thies account for the majority of liver transplants in paediatrics
and a signiﬁcant percentage of liver transplants in young adults.
Many cholangiopathies are congenital, resulting initially from an
altered development of the biliary tree, eventually accompanied
by necro-inﬂammatory processes [5,6]. For the clinical hepatolo-
gist, this means a good working knowledge of the mechanisms of
liver development is necessary for the care of these patients.
We will brieﬂy review the general aspects of bile duct devel-
opment and morphogenesis and the main molecular mechanisms
involved in bile duct ontogenesis. Then we will highlight the role
of these mechanisms in liver repair. Lastly, we will discuss the
cholangiopathies related to altered development, with a special
emphasis on those caused by a single genetic defect.General aspects of bile duct morphogenesis during liver
development
The liver develops as a tissue bud deriving from a diverticulum of
the ventral foregut endoderm, which extends into the septum
transversum, a structure located between the pericardial and per-
itoneal cavities. The ventral foregut endoderm develops two pro-
trusions: the cranial part leads to the formation of the
intrahepatic bile ducts, while the caudal part generates the extra-
hepatic biliary tree [1,7,8].
Intrahepatic biliary tree
The development of the intrahepatic biliary epithelium begins
around the 8th week of gestation (GW), and proceeds centrifu-
gally from the hilum to the periphery of the liver following the
portal vein system [5,6,9]. At birth, the intrahepatic biliary epi-
thelium is still immature, and its maturation is completed during
the ﬁrst years of life [9]. The sequence of events leading to the
development of the ductal plate and the intrahepatic bile ducts12 vol. 56 j 1159–1170
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Fig. 1. Embryological stages of intrahepatic bile duct development. The development of intrahepatic bile ducts starts when the periportal hepatoblasts, in close contact
with the portal mesenchyme surrounding a portal vein branch, begin to organise into a single layered sheath of small ﬂat epithelial cells, called ductal plate (‘‘ductal plate
stage’’, A). In the following weeks, discreet portions of the ductal plates are duplicated by a second layer of cells (double layered ductal plate, B), which then dilate to form
tubular structures in the process of being incorporated into the mesenchyma of the nascent portal space (incorporating bile duct, ‘‘migratory stage’’, C). Once incorporated
into the portal space, the immature tubules are remodelled into individualised bile ducts (incorporated bile duct, ‘‘bile duct stage’’, D).
Revieware shown in Fig. 1 [10–12]. Whether or not segments of the duc-
tal plate, that are not incorporated into the nascent bile ducts, are
gradually deleted by apoptosis is a matter of controversy. Recent
data from Lemaigre’s group [13] suggest that ductal plate remod-
elling does not occur by proliferation and apoptosis. Rather, por-
tions of the ductal plate appear to differentiate into periportal
hepatocytes and adult hepatic progenitor cells [13]. The role of
ductal plate cells as potential stem cells has been recently
addressed by Furuyama et al. [14]. A crucial event in the develop-
ment of the intrahepatic biliary system, as well as in liver repair,
is tubulogenesis. Biliary tubule formation depends upon a unique
process of transient asymmetry. Careful studies performed in
mouse embryos have shown that nascent tubules are formed
by ductal plate cells resembling cholangiocytes (positive for the
SRY-related HMG box transcription factor 9 [Sox9] and cytokera-
tin-19 [K19]) on the side facing the portal tract, and by ductal
plate cells resembling hepatoblasts (positive for the hepatocyte
nuclear factor 4 [HNF4] and the transforming growth factor
receptor type II [TbRII]) on the side facing the parenchyma. The
‘‘portal’’ layer shows higher levels of E-cadherin and is in contact
with laminin, while the ‘‘parenchymal’’ layer is characterised by
the apical expression of osteopontin [15]. After the formation of
a lumen, the nascent bile duct becomes symmetrical as ‘‘hepato-
blasts’’ are replaced by ‘‘cholangiocytes’’, and the ductal structure
matures along a cross-sectional axis and a cranio-caudal axis,
extending from the hilum to the periphery. Thus, the progressive
elongation of the duct requires a mechanism able to orient cell
mitoses along the aforementioned axes in a coordinated manner.
Through this mechanism, called ‘‘planar cell polarity’’ (PCP), the
epithelial cells are uniformly oriented within the ductal plane
to maintain the tubular architecture. PCP is a process that is con-
trolled by the non-canonical Wnt pathway, and is defective in
ﬁbropolycystic liver diseases (see below) [16].
The mechanisms that regulate the termination of biliary
development are not well known. Recent work from Kaestner’s
laboratory suggests that by inhibiting NF-jB-dependent cytokine
expression (speciﬁcally IL-6), the transcription factors Foxa1/2,
may act as a termination signal in bile duct development. Mice
with liver-speciﬁc deletion of both Foxa1 and Foxa2 showed an
increased amount of dysmorphic bile ducts [17]. On the other1160 Journal of Hepatology 2012hand, a decrease in Notch signalling could change the fate of
the non-duplicated ductal plate segments [18] and promote their
differentiation towards alternative pathways.
Extrahepatic biliary tree
Cholangiocytes lining the extrahepatic bile ducts derive from the
caudal part of the ventral foregut endoderm located between the
liver and the pancreatic buds, a region that expresses a combina-
tion of transcription factors common to the pancreas and duode-
num (Pdx-1, Prox-1, HNF-6). The extrahepatic part of the biliary
tree develops before the intrahepatic part; the two systems
merge at the level of the hepatic duct/hilum. Molecular mecha-
nisms regulating the development of the extrahepatic bile ducts
are less well known than those regulating the development of
the intrahepatic bile ducts. Mice deﬁcient in Pdx-1 [19] or Hes1
(a Notch-dependent transcription factor), HNF6, HNF-1b, or Foxf1
(a transcription factor target for the sonic Hedgehog signalling)
result in an altered development of the gallbladder and of the
common bile duct [20–22].Relationships between biliary and arterial development
Branches of the hepatic artery develop in close proximity to duc-
tal plates. On one side, the biliary epithelium guides arterial
development, on the other, the developing intrahepatic bile ducts
are nourished by the peribiliary plexus (PBP), a network of capil-
laries emerging from the ﬁnest branches of the hepatic artery at
the periphery of the liver lobule. PBP is crucial in maintaining the
integrity and function of the biliary epithelium [23–25].
The patterning of the intrahepatic biliary tree develops in
strict harmony with hepatic arteriogenesis. For example, inacti-
vation of Hnf6 or Hnf1ß, transcription factors involved in intrahe-
patic bile duct epithelium development, resulted in anomalies of
hepatic artery branches paralleling bile duct abnormalities [1,12].
One of the signals linking ductal and arterial development in the
liver is the vascular endothelial growth factor (VEGF), which
cooperates with angiopoietin-1 (Ang-1). The developing bile
ducts produce VEGF-A that in turn acts on endothelial cells andvol. 56 j 1159–1170
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their precursors, which both express the receptor VEGFR-2, to
promote arterial and PBP vasculogenesis. At the same time,
Ang-1 produced by hepatoblasts is likely to induce the matura-
tion of hepatic artery terminations by recruiting mural pericytes
to the nascent endothelial layer [12]. In ductal plate malforma-
tions (DPM), the dysmorphic bile ducts are surrounded by an
increased number of vascular structures [5,26,27]. For example,
in cystic cholangiopathies, the epithelium retains an immature
phenotype typical of the embryonic ductal plate coupled with
the production of VEGF and angiopoietins [26]. Production of
angiogenic factor by immature cholangiocytes promotes an
abundant pericystic vascularisation, thus providing the vascular
supply around the growing liver cysts [27] (see below).
The anatomical and functional association between bile duc-
tules and arterial vascularisation is maintained also in adult life
and during liver repair. A malfunction of this system may cause
ductopenia, as observed in chronic allograft rejection and in other
chronic cholangiopathies caused by an ischaemic damage [28].
Ductular reaction is a common histopathological response to
many forms of liver damage (see below); the increase in bile duc-
tules at the portal tract interface is paralleled by an increased
number of hepatic arterioles and capillaries [24,25]. These fea-
tures are reproduced in an experimental rat model of selective
cholangiocyte proliferation (a-naphthylisothiocyanate treat-
ment), where an extensive neovascularisation of the arterial
bed develops in strict conjunction with increased cholangiocyte
mass [29]. Furthermore, expansion of the biliary tree after bile
duct ligation in rat is also followed by substantial adaptive mod-
iﬁcations of the PBP [25,30].Transcription factors, growth factors and morphogens
involved in the ontogenesis of the biliary epithelium
At the time of liver speciﬁcation, i.e. when the endoderm
becomes committed towards a liver cell fate, liver development
is driven by several transcription factors including hepatocyte
nuclear factor 1b (HNF1b) [21,31], Foxa1 and Foxa2 [17], and
GATA-4 [32–34]. Extracellular signals, like ﬁbroblast growth
factor (FGF) secreted by the cardiogenic mesoderm [35], bone
morphogenetic protein-4 (BMP-4) and extracellular matrix con-
stituents [33,35], signal to competent cells and appear also to
be involved in biliary differentiation.
The differentiation of the intrahepatic biliary epithelium and
its tubular morphogenesis are ﬁnely regulated by signals
exchanged between epithelial cells and a variety of other non-
parenchymal cells. These signals encompass a series of
morphogens and growth factors that regulate the commitment
of hepatoblasts to the biliary lineage, or tubule formation by
cholangiocytes, or more often, both processes. The portal mesen-
chyme generates a portal to parenchymal gradient of transform-
ing growth factor-b (TGF-b2 and TGF-b3). TGF-b stimulates
hepatoblasts to undergo a switch towards a biliary phenotype
[36]. The developing ductal plates transitorily express the
TGF-b-receptor type II (TbRII); expression of TbRII is repressed
in differentiated cholangiocytes.
HNF6 and HNF1b are transcription factors able to regulate
multiple steps of biliary development and morphogenesis. Their
expression is upregulated in cholangiocytes and in progenitor
cells committed to the cholangiocyte lineage. In mice, their
absence is associated with cystic dysgenesis of the biliary treeJournal of Hepatology 2012[21,37]. HNF6 and HNF1b regulate distinct stages of bile duct
morphogenesis. Whereas the absence of HNF6 caused an early
defect in biliary cell differentiation, which can be somehow
repaired, a defect in HNF1b appears to be associated with a defect
in the maturation of the primitive ductal structure [38]. Further-
more, HNF6 stimulates expression of Pkhd1 while a deletion of
HNF1b causes an aberrant cystic development and defects in
PCP, a feature associated with ﬁbropolycystic liver diseases
[16]. It is noteworthy that HNF1b expression appears to be under
the control of Notch signalling.
Notch signalling is a fundamental mechanism that confers cell
fate instructions during the development of various tissues. Sev-
eral studies using genetic mouse models and zebraﬁsh demon-
strated that Notch signalling is required at different stages
during biliary tree development: from the formation of the ductal
plate to ductal plate remodelling and tubule formation [39,40].
The Notch genes encode four transmembrane receptors (Notch
1, 2, 3, and 4), which can interact with a number of ligands (Jag-
ged-1, Jagged-2, Delta-like 1, 3, and 4). Notch signalling requires
the establishment of cell–cell contacts. Through this interaction
among neighbouring cells, Notch receptors expressed by ‘‘receiv-
ing’’ cells are activated by the binding of ligands expressed on the
surface of ‘‘transmitting’’ cells. Notch may stimulate cells to
undergo a phenotypic switch through a process of ‘‘lateral induc-
tion’’. Alternatively, Notch may promote the maintenance of the
original phenotype through ‘‘lateral inhibition’’ [41]. In liver
development, Notch signalling appears to control the ability of
hepatoblasts and mature hepatocytes to differentiate into cholan-
giocytes by altering the expression of liver-enriched transcription
factors, and to regulate the formation of biliary tubules [18].
Notch-dependent signalling mechanisms are summarised in
Fig. 2. Notch drives the activation of Notch effector genes such
as Hairy and Enhancer of Split homologues (Hes1 and Hey-1),
via the transcription factor recombination signal binding protein
for immunoglobulin kappa J (RBP-Jk), which in turn activates
transcription factors speciﬁcally expressed by cholangiocytes,
including HNF1b and Sox9 [42].
Studies in mice have shown that Jagged-1 is expressed by per-
iportal mesenchymal cells and interacts with Notch-2 expressed
by hepatoblasts favouring their differentiation into ductal plate
cells. Perturbations in Jagged-1/Notch-2 interactions cause Ala-
gille syndrome (AGS), a genetic cholangiopathy characterised by
ductopenia and defective peripheral branching of the biliary tree
[43]. In fact, Jagged-1 inactivation in the portal vein mesenchy-
mal cells, but not in the endothelial cells, results in a defective
development of the bile ducts that do not mature beyond the ini-
tial formation of the ductal plate [44].
A major effect of Notch signalling is to modulate tubule for-
mation, a property that is necessary to effectively repair the bil-
iary tree. The effects of Notch receptors can be modiﬁed by
other ligands such as the glycosyltransferases encoded by Fringe
genes, and by the dosage of the Jagged-1 gene [45]. The impact of
Notch signalling on the intrahepatic bile duct branching is high-
lighted in a recent study by Sparks et al. [46], which demon-
strated that the density of three-dimensional peripheral
intrahepatic bile duct architecture during liver development
depends on Notch gene dosage.
Canonical Wingless (Wnt)/b-catenin participates in several
stages of bile duct development. Speciﬁc Wnt ligands, such as
Wnt3a, induce biliary differentiation, characterised by the
appearance of K19 positivity and generation of duct-likevol. 56 j 1159–1170 1161
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Fig. 2. Notch signalling. Jagged binding to a Notch receptor leads to the
proteolytic processing and subsequent translocation into the nucleus of the Notch
intracellular domain (NICD) of the receptor. Cleavage of NICD is an essential step
in this process and is mediated by a c-secretase enzyme in the cytoplasm. Once
delivered into the nucleus, NICD forms a complex with its DNA-binding partner,
the recombination signal binding protein for immunoglobulin kappa J (RBP-Jk).
The formation of this complex leads to the upregulation of cholangiocyte-speciﬁc
transcription factors, such as HNF1b and the SRY-related HGM box transcription
factor 9 (Sox9), and to the downregulation of hepatocyte-speciﬁc transcription
factors such as HNF1a and HNF4. Sox9 in particular, is the most speciﬁc and
earliest marker of biliary cells in the developing liver, as it controls the timing and
maturation of primitive ductal structures in tubulogenesis.
Table 1. Primary cholangiopathies related to altered biliary development.
Group Disease Gene defect Liver phenotype Clinical manifestations
Ductopenic 
syndromes
AGS Jagged1
Notch2
Ductopenia, reduced HPC and RDC, Pruritus
Jaundice
Failure to thrive
Malformative 
syndromes associated 
to DPM
Meckel syndrome MKS1 Ductal plate remnants
increased IHBC, mild portal fibrosis
Abort or perinatal death 
Joubert syndrome MKS3 and 
others 
Ductal plate remnants Abort or perinatal death
Polycystic 
liver diseases
ADPKD PKD1
PKD2
Cyst complications
Mass effect
Malnutrition
Renal failure
PLD PRKCSH
SEC63
Cyst complications
Mass effect
Malnutrition
Fibropolycystic 
liver diseases
ARPKD, CHF, CD PKHD1 Biliary microhamartomas with Acute cholangitis
Intrahepatic lithiasis
Portal hypertension
Risk for evolution to CCA
Liver cysts without peribiliary fibrosis
Liver cysts without peribiliary fibrosis
peribiliary fibrosis
AGS, Alagille syndrome; ADPKD, autosomal dominant polycystic kidney disease; PLD, polycystic liver disease; ARPKD, autosomal recessive polycystic kidney disease; CHF,
congenital hepatic ﬁbrosis; CD, Caroli’s disease.
Reviewstructures in mouse embryonic liver cell cultures. Wnt/b-catenin
appears to play a key role in biliary commitment, by repressing
hepatocyte differentiation and promoting ductal plate remodel-
ling [1,2]. The deletion of b-catenin in the developing hepato-
blasts in transgenic mice leads to a paucity of bile ducts and to
multiple defects in hepatoblast maturation, expansion, and sur-
vival [47]. Wnt can also signal through b-catenin-independent
pathways. Non-canonical Wnt pathways seem to be crucial in
the regulation of PCP [48], which is lost when Pkhd1, the gene
encoding for ﬁbrocystin (see below), is defective [16]. Notably,
inversin, a cilium-associated protein regulating the left–right
symmetry, modulates non-canonical Wnt signalling by interact-
ing directly with Dvl [49] and if defective, causes aberrant devel-
opment of intrahepatic bile ducts and cyst formation [16].
Canonical and non-canonical Wnt pathways are illustrated in
Fig. 3.
Similar to Notch and Wnt, Hedgehog signalling (Hh) is a mor-
phogenetic pathway involved in liver development. Signalling
mechanisms of the Hh pathway are shown in Fig. 4. On the con-
trary to stromal and progenitor cells, mature epithelial cells do
not retain the ability to respond to Hh signals. During develop-
ment, sonic Hh is expressed in the ventral foregut endoderm,
but its expression is then downregulated when the liver bud is
formed [50]. In the foetal liver, Hh and Gli1, transcription factors,
downstream of Hh signalling, are expressed in liver progenitor
cells but their expression disappears as soon as the development
proceeds. Therefore, activation of Hh signals is requested in a
temporally restricted manner to promote the early hepatoblast
proliferation, but then this pathway needs to be switched off to
allow hepatoblasts to differentiate normally [50].
In addition to differentiation and tissue remodelling, biliary
tubulogenesis requires cell proliferation. While the process of
remodelling depends on complex interactions with mesenchymal
and endothelial cells, tubule elongation is stimulated by a num-
ber of paracrine or autocrine factors, including oestrogens [51],
insulin-like growth factor-1 (IGF1) [52,53], interleukin-6 (IL-6)
[54], VEGF [26], which are able to stimulate cholangiocyte
proliferation.1162 Journal of Hepatology 2012When tubule formation ﬁnishes, cholangiocytes become qui-
escent. Expression of ciliary proteins and control of cytokine
secretion are important mechanisms involved in the terminationvol. 56 j 1159–1170
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Fig. 3. Wnt signalling (canonical and non-canonical). Wnt signals in two
different ways depending upon the activation (canonical) or the non-activation
(non canonical) of b-catenin. In the canonical Wnt pathway (A), the binding of
Wnt to Frizzled (Fzd) receptors activates Dishevelled (Dvl), which prevents the
phosphorylation and the following ubiquitination of b-catenin. If b-catenin is not
phosphorylated, it can thus accumulate in the cytoplasm and then translocate to
the nucleus, where it activates Wnt target genes by interacting with the TCF/LEF
family of transcription factors. In the non-canonical Wnt pathway (B), the binding
of speciﬁc Wnt isoforms (Wnt 4, 5a, 11) to Fzd can activate Dvl but the
downstream signal pathways involve small GTPases and the C-Jun N-terminal
kinase (JNK) instead of b-catenin. Once activated, Dvl leads to increased
intracellular Ca2+ levels that activate a number of proteins, including PKA, CaMK
and NFAT. Acting as transcription factors, these proteins may activate down-
stream effectors that are crucial regulators of different cellular responses, such as
planar cell polarity and cytoskeletal rearrangement.
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Fig. 4. Sonic Hedgehog (Shh) signalling. In physiological conditions (A), Patched
(Ptc) receptor binds to and consequently suppresses the function of its co-
receptor Smoothened (Smo). This maintains the bonding of the downstream
regulator Glioblastoma-3 (Gli3) to a tetramer complex encompassing its
suppressor factors, Suppressor Fused (Su(Fu)), Costal2 (Cos2), and Fused (Fu). In
this complex, Gli3 is proteolytically cleaved by protein kinase A (PKA), and
converted into the repressor form (Gli3R), which exerts an inhibitory effect on
nuclear transcription factors regulating Hh-responsive genes (Ptc, Gli1, Gli2).
When Shh interacts with Ptc (B), it prevents its inhibitory action on Smo.
Following Smo activation, the tetramer complex is disassembled so that Su(Fu)
inhibitory effect is restricted to Cos2 and PKA, thereby preventing the proteolytic
cleavage of Gli3. Gli3 can thus enter the nucleus in the activated state (Gli3A) to
promote activation of Hh target genes.
JOURNAL OF HEPATOLOGYof the developmental process. Foxa1 and Foxa2 are liver-speciﬁc
transcription factors, which play a crucial role in establishing the
developmental competence of the foregut endoderm and liver
speciﬁcation [17]. Interestingly, mice with liver-speciﬁc deletion
of Foxa1/2 develop dysmorphic and dilated bile ducts surrounded
by increased portal ﬁbrosis. These changes are, in part, caused by
the persistent expression of IL-6 by the biliary epithelium. In fact,
the IL-6 promoter is negatively regulated by Foxa1/2 through
binding to the glucocorticoid receptor. In absence of Foxa1/2,
IL-6 expression is not suppressed leading to both autocrine
effects on cholangiocytes (proliferation) and to paracrine effects
on inﬂammatory cells and myoﬁbroblasts (peribiliary ﬁbrosis)
[17]. This observation suggests that Foxa1/2 are among the tran-
scription factors involved in the termination of bile duct develop-
ment. Given the strong ability of reactive cholangiocytes to
secrete large amounts of IL-6, this mechanism can be relevant
also in liver repair (see below).Ductular reaction, a reparative response to biliary and
hepatocellular damage, is characterised by features
reminiscent of biliary ontogenesis
Mechanisms of liver repair recapitulating liver developmental
processes are an emerging concept. In fact, many molecularJournal of Hepatology 2012factors (growth factors, transcription factors, morphogens), tran-
siently engaged in the development of the biliary epithelium dur-
ing embryonic life, are reactivated in adulthood in response to
acute or chronic liver damage [12,55].
In the adult liver, the division of mature epithelial cells, i.e.
hepatocytes and/or cholangiocytes, drives normal tissue homeo-
stasis and regeneration after acute and transient hepatocellular
or biliary damage. On the other hand, in chronic liver diseases,
liver repair relies on the activation of hepatic progenitor cells
(HPC). HPC are bipotent cells located in close proximity to the
terminal cholangioles at their interface with the canals of Hering.
HPC are able to amplify and differentiate into cells committed to
hepatocellular or biliary lineages [56–59]. In humans, differenti-
ation towards hepatocytes occurs via intermediate hepato-biliary
cells (IHBC), whereas differentiation towards the biliary lineage
leads to the formation of reactive ductules (RDC) [59]. These cellu-
lar elements encompass the ‘‘hepatic reparative complex’’ and can
be recognised from their expression of cytokeratin-7 (K7) and/or
-19 (K19), cytoskeletal proteins present in the biliary lineage, but
not in hepatocytes (Fig. 5) [9,55]. Although transdifferentiation
from hepatocytes (formerly recognised as ‘‘ductular metaplasia’’
of hepatocytes) may occur under certain circumstances, reactive
ductules are believed to derive mostly from the progenitor cell
compartment.
Initially, RDC organise in clusters and do not encircle a lumen.
As RDC’s participation in tissue remodelling develops, they even-
tually reorganise into a richly anastomosing tubular network.vol. 56 j 1159–1170 1163
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Fig. 5. Epithelial phenotypes involved in liver repair driven by the activation
of hepatic progenitor cells (‘‘Hepatic Reparative Complex’’). In acute and
chronic liver diseases, especially in fulminant hepatic failure, liver repair is driven
by the activation of hepatic progenitor cells (HPC) to differentiate into hepato-
cytes and/or cholangiocytes. However, hepatocyte and cholangiocyte prolifera-
tion can be directly stimulated without exploiting HPC activation in experimental
models, such as partial hepatectomy and acute biliary obstruction, respectively.
HPC are small epithelial cells with an oval nucleus and scant cytoplasm, similar to
oval cells in rodents treated with carcinogens. HPC originate from a niche located
in the smaller branches of the biliary tree and in the canals of Hering. HPC behave
as a bipotent, transit amplifying compartment. Differentiation of HPC towards
hepatocytes occurs via intermediate hepatobiliary cells (IHBC), while differenti-
ation towards the biliary lineage leads to the formation of reactive ductular cells
(RDC). HPC, IHBC and RDC constitute the ‘‘hepatic reparative complex’’, and can be
distinguished by morphology and pattern of K7 expression. Whereas Wnt
signalling is a key regulator of proliferation of HPC, Notch and Hh signalling are
mostly involved in biliary differentiation through RDC generation, along with
other cytokines released from the inﬂammatory microenvironment (TNF-a,
TWEAK, TGF-b, HGF, VEGF, IL-6) (see text for details).
ReviewTubule formation during biliary repair is a fundamental process
aimed at generating a compensatory increase of the ductal mass
to prevent the development of extensive liver necrosis due to the
leakage of bile into the parenchyma. It is important to recognise
that activation and proliferation of HPC is not sufﬁcient to repair
biliary damage unless progenitor cells and reactive cholangio-
cytes acquire the ability to form new branching tubular struc-
tures, thus restoring the ductal mass [60].
In addition to replacement of damaged cells and development
of branching tubules, liver repair requires the generation of a
ﬁbro-vascular stroma able to sustain and feed the remodelling1164 Journal of Hepatology 2012ductal structures. As a consequence, RDC de novo express a vari-
ety of cytokines, chemokines, growth factors, angiogenic factors
and adhesion molecules, along with their receptors. This property
enables RDC to establish an extensive crosstalk with other liver
cell types, including hepatocytes, stellate cells and endothelial
cells (Fig. 6) [61]. When the biliary tree is damaged, these inter-
actions become functionally relevant leading to a signiﬁcant
expansion of the reactive cholangiocyte compartment. Most of
the molecular signatures expressed by reactive cholangiocytes,
including VEGF [12], TGF-b2 [62], connective tissue growth factor
(CTGF) [63], stromal cell-derived factor 1 (SDF-1) [64], IL-6 [65],
tumour necrosis factor-a (TNFa) [65], neural cell adhesion mole-
cule (NCAM) and Bcl-2 [55], are transiently expressed by ductal
plate cells in foetal life, consistent with the concept that ductular
reaction recapitulates liver ontogenesis [55,66–68] (Fig. 7).
The molecular mechanisms that activate ductular reaction
require a ﬁnely coordinated process that also shares a number
of similarities with biliary embryogenesis. Ductular reaction is
elicited by inﬂammatory signals released from the local microen-
vironment. TNF-a [69], TWEAK [70], TGF-b [71], HGF [71], VEGF
[26,72], sonic Hedgehog (shh) [73], and Wnt/b-catenin [74] sig-
nalling are among the key signalling pathways. As mentioned
above, proliferation of reactive cholangiocytes may be achieved
by switching off transcription factors (Foxa1/2) used to terminate
development. Unfortunately, activation/deactivation of develop-
mental mechanisms in the context of non-resolving inﬂamma-
tion, leads to the development of portal ﬁbrosis in
cholangiopathies. The ability of ‘‘reactive’’ cholangiocytes to
recruit inﬂammatory, vascular and mesenchymal cells, with
which they exchange a variety of paracrine signals, subsequently
leads to excessive collagen deposition and stimulation of angio-
genesis, and ultimately to cirrhosis [75].
Several morphogens involved in biliary development, such as
Wnt, Hedgehog, and Notch, also play a pivotal role in liver repair.
Recent ﬁndings suggest that the Wnt/b-catenin pathway is
strongly involved in the normal activation and proliferation of
adult HPC in both acute and chronic human liver diseases [76].
Oval cell activation in b-catenin conditional knockout mice was
dramatically reduced, after chemical treatment to induce acute
liver damage [77].
Whereas Wnt signalling is a key regulator of proliferation of
HPC, Notch signalling is mostly involved in biliary differentiation.
The role of Notch is underscored by the peculiar liver phenotype
observed in AGS. AGS is characterised by a marked reduction in
RDC and HPC, in sharp contrast with biliary atresia, which is a
congenital cholangiopathy with similar levels of homeostasis
but much faster evolution to biliary cirrhosis [43]. This difference
is likely related to a Notch-dependent block in cell fate determi-
nation upstream of HNF1b. Recent data from our group show that
following treatment with cholestatic agents, HPC activation and
tubule formation are dramatically impaired in mice with a
liver-speciﬁc defect in RBP-Jk [78].
In addition to Notch, Hh signalling is also relevant in congen-
ital cholangiopathies. Perturbations in the Hh signalling have
been associated with DPM in Meckel syndrome (MKS), a rare
autosomal recessive disease caused by a defect in MKS1 gene
encoding a protein associated with the base of cilia. MKS causes
perinatal lethality and is characterised by a complex syndrome
including polycystic kidneys, occipital meningoencephalocele,
postaxial polydactyly in addition to DPM [79]. In liver repair, acti-
vation of the Hh signalling promotes the expansion of a subset ofvol. 56 j 1159–1170
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Fig. 6. Reactive ductular cells acquire the ability to exchange a range of
paracrine signals with mesenchymal, vascular and inﬂammatory cells. Owing
to the de novo expression of a variety of cytokines, chemokines, growth factors,
angiogenic factors, together with a rich expression of many of the respective
cognate receptors, reactive ductular cells can establish an extensive crosstalk
with other liver cell types, particularly with stellate cells, endothelial cells and
inﬂammatory cells. In response to biliary damage, these interactions become
functionally relevant leading to the generation of a ﬁbro-vascular stroma able to
sustain and feed the ductular reaction, and to the recruitment of a peribiliary
inﬂammatory inﬁltrate which further enhances the bile duct damage.
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Fig. 7. Phenotypic changes of ductular reactive cells shared with ductal plate
cells. An important feature of reactive cholangiocytes is the foetal reminiscence of
their phenotype. Reactive ductular cells express neuroendocrine features, adhe-
sion molecules, cytokines and chemokines, receptors and other metabolically
active molecules, which are transiently expressed by ductal plate cells during
embryonic development.
JOURNAL OF HEPATOLOGYimmature ductular cells that co-express mesenchymal markers
and may be proﬁbrogenic [80]. This mechanism is relevant inJournal of Hepatology 2012biliary atresia, where excessive activation of Hh signalling halts
bile duct morphogenesis and promotes accumulation of imma-
ture ductular cells with a mesenchymal phenotype, which in turn
enhance ﬁbrogenesis [81]. These data suggest that aberrant acti-
vation of Hh signalling may be responsible for biliary ﬁbrosis fea-
turing developmental cholangiopathies.Primary cholangiopathies related to an altered development
of the biliary epithelium
Cholangiopathies related to altered biliary development [5,82]
(Table 1) represent important disease models; understanding
their pathogenetic mechanisms offers important clues on how
speciﬁc genes regulating developmental processes are involved
in biliary repair and reaction to damage. Recently, based on the
phenotype of several mouse models with speciﬁc defects of bili-
ary morphogenesis, DPM have been classiﬁed into three groups,
with: (a) defective differentiation of biliary precursors cells
(HNF6 deﬁciency), (b) defective maturation of primitive ductal
structure (HNF1b deﬁciency) or (c) defective duct expansion dur-
ing development with preserved biliary differentiation (cystin-1
deﬁciency) [38]. Most DPM are embryonically lethal or are part
of complex syndromic diseases. Herein, we will outline the most
recent advances in the pathogenesis of congenital cholangiopa-
thies that may be clinically relevant for both paediatric and adult
clinical hepatologists. The most common DPM are the Von Mey-
enburg complexes, also known as biliary microhamartomas
(Fig. 8B). These are benign lesions characterised by irregularly
shaped and dilated biliary structures, embedded in a dense
ﬁbrous stroma. Their distribution is generally focal, but when dif-
fuse they can be associated with cystic lesions, as seen in congen-
ital hepatic ﬁbrosis (see below) [6]. Von Meyenburg complexes
have also been found in higher numbers in the liver of patients
with autosomal dominant polycystic kidney disease [83,84]. The
association of Von Meyenburg complexes to cholangiocarcinoma
is uncommon, but it has been sporadically described [85–87].
Autosomal recessive polycystic kidney disease (ARPKD), congenital
hepatic ﬁbrosis (CHF) and Caroli’s disease (CD)
The presence of ductal plate remnants, Von Meyenburg com-
plexes, and biliary cysts variably associated with an intense
peribiliary ﬁbrosis, are the main features of ﬁbropolycystic dis-
eases [6]. These include ARPKD, and its hepatic variants, CHF
and CD, and a variety of congenital syndromes (Meckel and Jou-
bert syndromes), which are often embryonically lethal. In CHF
and CD, biliary malformations are associated with progressive
portal ﬁbrosis leading to portal hypertension, without progress-
ing to frank cirrhosis. In patients with CD, the risk of developing
cholangiocarcinoma is substantially increased (about 10%).
CHF and CD are caused by mutations in PKHD1, a gene encod-
ing for ﬁbrocystin (FPC). FPC is a large membrane, receptor-like
protein expressed by the basal body of cilia, subcellular organ-
elles that sense the direction of ductal bile ﬂow, and by centro-
meres of renal tubular and bile duct epithelial cells [88–90].
Although FPC functions are largely unknown, some of its proper-
ties have been recently outlined [91]. FPC is thought to be
involved in a variety of functions, from proliferation to secretion,
terminal differentiation, tubulogenesis, and interactions with the
extracellular matrix. Silencing Pkhd1 in cultured mouse renalvol. 56 j 1159–1170 1165
Fig. 8. Main differences in liver phenotype between ARPKD and ADPKD. On
magnetic resonance imaging, liver cysts appear as focal lesions with regular
margins, which are of small size and in continuity with the biliary tree in ARPKD
(A), whereas they are large, of different size and scattered throughout the hepatic
parenchyma leading to extensive cyst substitution in ADPKD (D). At histological
examination, irregularly shaped biliary structures (microhamartomas) sur-
rounded by an extensive deposition of ﬁbrotic tissue, are present in the portal
tracts in ARPKD (B, H&E; magniﬁcation: 100), while in ADPKD, biliary cysts
appear as large, circular biliary structures, lined by cuboidal or ﬂattened
epithelium, with negligible amount of peribiliary ﬁbrosis (E, H&E, magniﬁcation:
100). The pathogenetic mechanism underlying cyst formation is characterised
by progressive segmental dilation of biliary structures which maintain their
connection to the biliary tree in ARPKD (C), whereas biliary cysts detach from the
bile duct and then progressively increase in size in ADPKD (F). Alternatively,
based on previous histopathological studies [110–112], liver cysts in ADPKD may
also derive from dilatation of components of Von Meyenburg complexes.
Reviewtubular cells altered cytoskeletal organisation and impaired cell–
cell and cell–matrix contacts [92]. Recent evidences indicate that
FPC is also involved in planar cell polarity. In the Pck rat, a model
orthologue of ARPKD, FPC deﬁciency is strongly correlated with
the loss of PCP at the renal level. This leads to a perturbed mitotic
alignment on circumferential tubular cell number expansion,
which is ultimately responsible for renal tubular enlargement
and cyst formation [16]. The mechanistic relationships between
biliary dysgenesis and portal ﬁbrosis are not understood and this
is an area of current investigation.
Autosomal dominant polycystic kidney disease (ADPKD) and
polycystic liver disease (PLD)
Autosomal dominant polycystic kidney disease (ADPKD) and
polycystic liver disease (PLD) are inherited with an autosomal1166 Journal of Hepatology 2012dominant transmission. These conditions do not cause signiﬁcant
liver ﬁbrosis, but rather an enormous increase in liver mass. The
formation and progressive enlargement of multiple cysts scat-
tered throughout the liver parenchyma characterise both ADPKD
and PLD [93]. Despite extensive cyst substitution of the hepatic
parenchyma, liver function is generally well preserved and portal
hypertension is rare.
The patients are usually asymptomatic, unless acute and
chronic complications (including cyst infections or bleeding and
mass effect) develop. ADPKD is caused by mutations in the
PKD1 or PKD2 genes [94,95]. The transcribed products of these
two genes, polycystin-1 (PC1) and polycystin-2 (PC2), are mem-
brane proteins located in the renal tubular and biliary epithelia.
PC1 and PC2 regulate signalling pathways that are involved in
epithelial cell morphogenesis, differentiation and proliferation.
In conditional, liver speciﬁc mice defective for PC-1 or PC-2, poly-
cystic liver disease develops even if PC1 and PC2 are deleted after
birth, indicating that PC expression maintain a fundamental mor-
phogenetic role also during adult life [27,96]. Thus, altered PC
function may cause a lack of differentiating signals favouring
the maintenance of an immature and proliferative phenotype
by biliary epithelial cells ultimately responsible for cyst forma-
tion. In fact, cholangiocytes lining the liver cysts present strong
phenotypic and functional similarities with ductal plate/reactive
ductules [26]. Among them are an aberrant secretion of several
cytokines and chemokines, including IL-6 [97], IL-8 [97], and
CXCR2 [98], a marked overexpression of oestrogen receptors,
IGF1, the IGF1 and growth hormone receptors as well as VEGF
and its cognate receptor, VEGFR-2 [26]. In particular, VEGF
potently stimulates the progression of liver cysts in ADPKD via
autocrine stimulation of cholangiocyte proliferation and para-
crine promotion of pericystic angiogenesis. We have shown that
in cystic cholangiocytes from Pkd2-defective mice a MEK/ERK1/
2/mTOR pathway is overactive and is responsible for increased
hypoxia-inducible factor 1a-dependent VEGF production and
increased VEGFR-2-mediated autocrine stimulation of cyst
growth. This mechanism represents a potential target for therapy,
as the blockade of angiogenic signalling using a competitive
inhibitor of VEGFR-2, or the administration of mTOR inhibitors
block the growth of liver cysts in Pkd2KO mice, and reduces the
proliferative activity of the cystic epithelium [96]. Overall, these
data indicate that polycystic liver diseases should be considered
as congenital diseases of cholangiocyte signalling [99]. Pheno-
typic changes in cyst cholangiocytes with functional relevance
for cyst formation and progression are summarised in Table 2.
Each pathway is also therapeutically relevant as a potential target
amenable of pharmacological interference aimed at reducing dis-
ease progression. Future studies will clarify whether the use of
agents interfering with VEGF or mTOR signalling can be clinically
useful and if their use can be extended to other cholangiopathies
[27].
In PLD, genetic defects do not involve ciliary proteins. PLD is
caused by mutations in PRKCSH, a gene encoding for protein
kinase C substrate 80K-H also called hepatocystin [100], or in
the SEC63 gene [101]. SEC63 encodes a component of the molec-
ular machinery regulating translocation and folding of newly
synthesised membrane glycoproteins. Hepatocystin and SEC63
are expressed on the endoplasmic reticulum (ER) [102], and
defects in other enzymatic activities associated with the ER, such
as xylosyl transferase 2 responsible for initiating heparin sul-
phate and chondroitin sulphate biosynthesis, have been linkedvol. 56 j 1159–1170
Table 2. Phenotypic changes in cyst cholangiocytes.
• Less differentiated phenotype
• VEGF and VEGFR2 expression
• Cytokines and chemokines secretion
• Lower cytoplasmic [Ca2+]
• Increased cAMP levels
• Increased expression of mTOR, pERK1/2
• Increased proliferation/apoptosis
• Changes in ER functions
• Altered non-canonical Wnt signaling
JOURNAL OF HEPATOLOGYto the development of renal and liver cysts [103]. PLD serves to
highlight the important concept that cystic liver disease does
not necessarily derive from ciliary dysfunction, but that the
defective proteins are expressed in multiple cellular locations,
including the ER.Alagille syndrome (AGS)
Alagille syndrome (AGS) is a complex, multisystemic disorder
inherited as an autosomal dominant trait and characterised by
ductopenia. AGS exhibits a wide range of extrahepatic manifesta-
tions (cardiac, vascular, skeletal, ocular, facial, renal, central ner-
vous system), hence the term of ‘‘syndromic bile duct paucity’’
[104,105]. The hepatic phenotype is recognised by variable
degrees of cholestasis, jaundice and pruritus. Fibrosis is not a
prominent feature of AGS and frank evolution to cirrhosis is rare,
however, rare cases lead to liver transplantation [106]. In nearly
80% of AGS patients, a mutation in the genes JAGGED1 [107,108],
or less frequently, NOTCH2 can be identiﬁed [109]. AGS differs
from other cholestatic cholangiopathies in the extent and sever-
ity of ductular reaction. The near absence of HPC and RDC in AGS
(Fig. 5) is conversely coupled with an extensive accumulation of
IHBC. IHBC do not express the biliary speciﬁc transcription factor
HNF1b, whose expression is controlled by Notch signalling [43].
This imbalance in the cellular elements of the ‘‘hepatic reparative
complex’’, which is a peculiar histopathological feature of AGS,
supports the concept that Notch signalling plays an essential role
in liver repair by regulating the generation of biliary committed
precursors as well as the branching tubularisation [78].Conclusions
Several cholangiopathies are caused by a malfunction of develop-
mental mechanisms. In these diseases, cholangiocyte dysfunction
is often caused by a speciﬁc genetic defect relevant to morpho-
genesis. Also, cholangiocytes express a range of phenotypic fea-
tures reminiscent of foetal behaviour. In different forms of
acquired liver damage, liver repair exploits several developmen-
tal mechanisms, in a sort of ‘‘recapitulation of ontogenesis’’. Duc-
tular reactive cells generated in response to liver damage express
several of the autocrine and paracrine signals transitorily
expressed by ductal plate cells during liver development. There-
fore, understanding the molecular mechanisms regulating devel-
opment of the biliary tree may help solve several challengingJournal of Hepatology 2012issues facing modern Hepatology. These may range from the
search of novel treatments for patients with biliary diseases, to
the need of limit/prevent pathologic repair in chronic liver dis-
eases, to the design of bioartiﬁcial liver support devices, to strat-
egies for liver regenerative medicine.Key Points
• Intrahepatic and extrahepatic bile ducts have different 
embryologic origins. Whereas cholangiocytes lining the 
intrahepatic bile ducts derive from hepatoblasts, extra-
hepatic cholangiocytes derive from the caudal part of the 
ventral foregut endoderm
• Signals from the portal mesenchyma stimulate 
hepatoblasts to differentiate into ductal plate cells. After 
ductal plate duplication, biliary tubule formation requires 
a process of transient asymmetry that proceeds from the 
hilum to the periphery of the liver and is completed only 
after birth. A number of transcription factors and 
signaling is involved in multiple steps, from ductal plate 
formation to ductal plate remodeling and tubularisation
• Ductal plate malformations are caused by genetic 
defects in proteins expressed in multiple cellular 
locations, including primary cilia and the endoplasmic 
reticulum. Phenotypic features reminiscent of ductal 
plate cells are also expressed by cholangiocytes layering 
liver cysts and microhamartomas in developmental 
cholangiopathies. Cholangiopathies are a group of 
diseases in which cholangiocyte dysfunction is often 
morphogenesis
• Ductular reaction is a common compensatory and 
reparative response to different forms of liver 
damage, which recapitulates ontogenesis. In fact, ductal 
plates transitorily express several of the autocrine and 
paracrine signals generated by ductular reactive cells in 
response to liver damage, during liver development
• Understanding the molecular mechanisms regulating 
development of the biliary tree in embryonic life provides 
invaluable clues on the mechanisms underlying epithelial 
reaction and liver damage in adulthood
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